Over the past decade, the role of proton pump inhibitor (PPI) medication has evolved from a
diagnostic tool for Eosinophilic Esophagitis (EoE), by excluding patients with PPI responsive …

ABSTRACT Introduction Proton pump inhibitors (PPIs) block the gastric H/K-ATPase,
therefore inhibiting acid gastric secretion, leading to an increased pH (> 4). They account for …

Context It is still debated whether prolonged use of proton pump inhibitors (PPIs) might affect
metabolic health. Objective To investigate the relationship between prolonged use of PPIs …

Exposure to proton pump inhibitors and risk of diabetes: A systematic review and meta-analysis
- PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …

Abstract Interpretation of existing data revealed that chronic metabolic acidosis is a
pathognomic feature for type 2 diabetes (T2D), which is described here as “chronic …

Diabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia as a
result of insufficient insulin levels and/or impaired function as a result of autoimmune …

Background: Proton pump inhibitors (PPIs) are an extensively prescribed class of anti-ulcer
drugs. This systematic review aimed to investigate the association between PPI use and the …

Proton pump inhibitors (PPIs) are one of the most prescribed drugs around the world. PPIs
induce microbiota modulation such as obesity both in humans and in animal models …

Statins might exert diabetogenic effects, potentially increasing insulin resistance and
worsening glucose control. However, patients with diabetes mellitus are at high or very high …

Several observational studies have suggested that proton‐pump inhibitor (PPI) use might
increase diabetes risk, but the mechanism remains unclear. This study aimed to investigate …